Contrary to current UK recommendations, both panels supported proactive conversations between primary care HCPs and patients at higher-than-average risk because of Black ethnicity, or a family history of prostate cancer, or confirmed genetic risk factors (for example, BRCA2 gene mutation). The gene discussed is BRCA2; the disease is Familial prostate cancer.